Market Research Blog – Page 2173 – New Product Development

Global Dry Eye Syndrome Treatment Industry Set to Boom: Projected CAGR of 6.4% to Reach US$9.52 Billion by 2033 | FMI Study

Relief for dry eyes is on the horizon! The Global Dry Eye Syndrome Treatment Industry is projected for significant growth, with a robust Compound Annual Growth Rate (CAGR) of 6.4% anticipated over the next ten years. This promising outlook is based on a recent market analysis, which reveals a current market value of US$5.12 billion in 2023. By 2033, the market is expected to reach a staggering US$9.52 billion, reflecting a growing demand for effective solutions to alleviate dry eye symptoms.

Dry Eye Syndrome, a common ocular condition affecting millions worldwide, is characterized by discomfort, irritation, and blurred vision. This significant market growth reflects the increasing demand for effective treatment options. Advancements in eye care are introducing innovative therapies, offering relief and improved quality of life for millions struggling with DES.

Request a Sample of this Report Using a Work Email To Get a Quick Reply!
https://www.futuremarketinsights.com/reports/sample/rep-gb-1215

One such example is the Narayana Nethralaya, a super specialty eye hospital based out of India, with a dedicated lab to diagnose and treat dry eyes. This lab aims to provide patients with awareness about eyelid problems such as Meibomian gland dysfunction, which leads to the development of dry eye syndrome.

Also, a similar trend is observed in developed markets such as the U.S. Various government awareness campaigns and not-for-profit initiatives try to create awareness about dry eye disease among the population that does not have access to eye care facilities. Eye Care America is an example of a public service organization run by the American Academy of Ophthalmology Foundation that provides free eye care through volunteer ophthalmologists.

Further, those who are age 65 or older and who have not seen an ophthalmologist in three or more years may be eligible to receive a comprehensive, medical eye exam and up to one year of care at no out-of-pocket cost. This consequently will increase the utilization of dry eye treatment products and drive the growth of the Dry Eye Syndrome Treatment Industry during the forecast period. .

Key Takeaways from Global Dry Eye Syndrome Treatment Industry Study

Greater acceptance of artificial tears owing to improved patient comfort leads the artificial tears segment to account for the maximum share of 60.8% in 2021, expanding at 7.1% CAGR during the forecast period.
By prescription, Rx prescriptions are projected to account for 71.3% of the market share in 2022 indicating the highest demand, since the majority of the population visits hospitals to get the checkup done, in turn increasing the numbers of Rx prescriptions.
Retail pharmacies, as distribution channels held the largest share of 60.8% in 2021 and are expected to grow with the same trend throughout the forecast period.
By region, North America held the largest share of 37.6% of the Dry Eye Syndrome Treatment Industry in 2021 indicating the growth due to high prevalence and high treatment adoption rate in North America.

“Growing incidence of dry eye syndrome due to growing aging population, and long working hours (increase in screen time) to drive the demand of Dry Eye Syndrome treatment products over the Decade,” says the FMI Analyst

Who is winning?

Global Dry Eye Syndrome Treatment Industry Key Players :

Allergen plc. (Abbvie)
Novartis AG
Otsuka Pharmaceuticals Co.Ltd.
Bausch Health Companies Inc.
Akron Inc.
Johnson & Johnson Inc.
Thea Pharmaceuticals Limited
OASIS Medical
Altaire Pharmaceuticals Inc.
Boiron USA
Similasan Corporation
Scope Ophthalmics Ltd.
Reckitt Benckiser Group PLC
Medicom Healthcare Ltd
FDC Limited.
Lupin Limited
Jamjoom Pharmaceuticals Co.
Sentiss Pharma Private Limited.

Some of the leading manufacturers of the global dry-eye-syndrome treatment industry focus on the product launch and approvals with global expansion objectives, thereby, enhancing their market presence.

In January 2021, SIFI an Italy-based international ophthalmic company launched SYNFO for moisturizing and lubrication in dry eye treatment.
In December 2020, Alcon Canada announced the launch of its new product Systane an ultra-hydration lubricant eye drops preservative free containing Hyaluronic acid and HP-guar
In November 2020, Santen Pharmaceutical launched Cationorm categorized as an artificial tear for moisturisation and long-lasting relief to dry eye.

Get Your Customized Impactful Report Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-1215

Want more insights?

Future Market Insights brings a comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global Dry Eye Syndrome Treatment Industry is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

The study provides compelling insights on Dry Eye Syndrome Treatment Industry segment based on Product (Cyclosporine, Topical Corticosteroids, and Artificial Tears Punctal Plugs (removable, dissolvable), oral omega supplements, and others), prescription (Rx, OTC, Medical Devices), distribution channel (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, and Online Pharmacies) across seven major regions.

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global High Content Screening Market Set to Flourish, Expected to Reach USD 3 Billion in 2033 at a 5.8% of CAGR

The global High-Content Screening market is poised for positive growth, with an anticipated valuation of USD 1.6 billion in 2022. According to market forecasts, the demand for high content screening is expected to surge at a Compound Annual Growth Rate (CAGR) of 5.8% over the forecast period, reflecting the increasing adoption and advancements in high content screening technologies.

High content screening (HCS) is a powerful analytical method used in drug discovery and cell biology to conduct automated microscopy and quantitative analysis of cellular events. The growth in the HCS market is driven by the rising need for sophisticated screening techniques in drug discovery, the increasing prevalence of chronic diseases, and advancements in imaging technologies.

Your Insightful Report Sample With Your Work Email:
https://www.futuremarketinsights.com/reports/sample/rep-gb-426

Finding and developing new drugs involves the use of high content screening. The increasing amount of research being done on target identification and validation, along with the ongoing quest for new drug candidates, is predicted to drive an acceleration in the adoption of high content screening over the next few years. Furthermore, it is projected that demand will rise over the course of the projection period as a result of a continued emphasis on manufacturing high-quality and technologically advanced cell imaging systems.

Nevertheless, the COVID-19 pandemic significantly impeded investigations and advancements. The market is anticipated to suffer as a result of this. However, it is anticipated that the market will grow in the upcoming years due to a rise in the amount of money major manufacturers are investing in the creation of cutting-edge cell imaging products.

Key Takeaways

The CAGR for the global market over the preceding period was 5.1%.
Over the coming decades, the market in India is anticipated to grow at a CAGR of 6.6%.
With more than 7.3% of all demand recorded in Europe in 2022, Germany has emerged as a major market.
Over the coming decade, the market in China is anticipated to grow at a CAGR of 7.8%.
The highest demand for High Content Screenings came from the pharmaceutical and healthcare industries.

“The rising prevalence of multiple infectious diseases with a variety of symptoms raises the demand for innovative treatments. As a result, there will be an increase in biotechnology and pharmaceutical study and development efforts to identify new drug candidates. Imaging technologies are becoming increasingly important in drug discovery and analysis.” says an FMI analyst.

Competitive Landscape:

Key players in the HCS market employ strategies such as mergers and acquisitions, product launches, collaborations, and alliances to expand their businesses.

Particle Works, a progressive company that creates and markets cutting-edge particle engineering platforms, declared the release of the Automated Library Synthesis (ALiS) System, a new ground-breaking platform, in November 2022. This innovative platform favors automation in the early stages of the creation of drugs as well as high-throughput evaluation of lipid nanoparticle (LNP) formulations and mRNA candidates.
The Twist High Throughput Antibody Production platform, developed by California-based Twist Bioscience Corporation, was made public in April 2022. It allows customers to convert candidate genetic sequences into cleansed antibodies for use in a variety of applications related to screening and therapeutic discovery projects.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-426

Key Companies Profiled:

Thermo Fisher Scientific Inc.
Becton Dickinson, and Company
GE Healthcare
Olympus Corporation
PerkinElmer Inc.
Sysmex Corporation
Merck KGaA
Danaher Corporation
Yokogawa Electric Corporation
BioTek Instruments Inc.

Key Segments Profiled in the High Content Screening Industry Survey:

Product Type:

Cell Imaging & Analysis
- HCS Instruments
  - High-End HCS
  - Mid End HCS
  - Low-End HCS
- Flow Cytometers
Consumables
- Microplates
- Reagents & Assay Kits
- Other Consumables
Software
Services

Industry:

Pharmaceutical & Healthcare
Biotechnology
Educational Institutions
Independent CRO
Government Organizations
Others

Application:

Primary & Secondary Screening
Target Identification & Validation
Toxicity Studies
Compound Profiling
Others

Region:

North America
Latin America
Europe
Asia Pacific
Middle East and Africa

Get Full Market Analysis Now: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/426

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Middle East Veterinary Vaccines Set for Steady Growth at 4% CAGR, Reaching US$973.8 Million by 2033 | FMI Study

The Middle East Veterinary Vaccines is poised for a period of sustained growth, driven by increasing pet ownership and growing awareness of animal health. According to a recent analysis, the market is expected to witness a Compound Annual Growth Rate (CAGR) of 4% through 2033.

Rising Demand for Veterinary Vaccines:

The demand for veterinary vaccines in the Middle East is projected to reach US$627.1 million in 2023. This figure is anticipated to climb steadily, with sales reaching a staggering US$973.8 million by 2033.

The demand for veterinary vaccines has increased over the past few years due to the increasing incidences of foodborne and zoonotic infections among the population in the Middle Eastern region. The pattern of veterinary treatment is shifting from curative/reactive to preventive in these countries. The cost of preventive treatment is much smaller and has far fewer side effects than reactive treatments that often lead to mass slaughter.

Request a Sample of this Report Using a Work Email To Get a Quick Reply!
https://www.futuremarketinsights.com/reports/sample/rep-ma-3086

The rebound of economic prosperity in MEA markets is expected to contribute towards increased demand for processed healthy meat products. This will fuel the demand for effective vaccination of livestock, especially in major animal farming and meat-producing nations in the region with a diversified herd such as Sudan, Turkey, Egypt, and KSA.

Rising per capita disposable income levels are largely contributing to the demand for processed food items. This is expected to drive the growth of veterinary vaccines in poultry and livestock segments.

The key players in the veterinary vaccine industry are focusing on finding innovative products to control zoonotic infection rates. Along with this, various advancements in biotechnology are expected to create a favorable platform for the development of various veterinary vaccines in developing markets such as UAE, KSA, Turkey, and Jordan. These techniques include next-generation sequencing, synthetic biology, and systems biology, among others.

Further, continued investments in multi-disciplinary vaccinology research could improve vaccine development efficiency and shorten the time-to-market for upcoming veterinary vaccines.

Key players are working on innovative products, conducting acquisitions, mergers, and agreements with other companies to improve their market presence and tap into less competitive emerging markets.

For instance, In September 2018, Boehringer Ingelheim announced that they would be donating 75,000 doses of rabies vaccines to the Global Alliance for Rabies Control, as an effort to recognize World Rabies Day on September 28^th.

Such developments not only strengthen the company’s existing portfolio but also help to increase their presence at the regional as well as global level and help companies to sustain the increasing competitive pressure.

Middle East Veterinary Vaccines Key Takeaways:

Robust Growth Projection: The Middle East veterinary vaccine industry is poised for a substantial 4% CAGR growth, showcasing a promising future for the region’s veterinary healthcare.
Current Demand Outlook: In 2023, the demand for veterinary vaccines in the Middle East is projected to reach US$ 627.1 million, indicating a strong market presence.
Anticipated Valuation Surge: By 2033, the sales of veterinary vaccines in the Middle East are expected to surpass US$ 973.8 million, reflecting a significant uptick in market value.
Critical Role in Animal Health: The escalating demand for veterinary vaccines underlines their crucial role in maintaining the health and well-being of animals in the region.

“Increased demand for processed meat products around the world will drive the demand for veterinary vaccines market in the Middle East,” says the FMI Analyst.

Who is winning?

The key manufacturers of the veterinary vaccines market are adopting strategies such as partnership strategies for global expansion and improving their hold over the global market.

In January 2021, Merck Animal Health announced the acquisition of Poultry Sense Ltd, which provides health and environmental monitoring solutions for the poultry industry.

In September 2019, Ceva, in partnership with Biotecon Diagnostics, announced the launch of their latest product, a real-time diagnostic kit that will help poultry producers fight salmonella infections in their farms.

The key market players of the Middle East Veterinary Vaccines include :

JOVA, Bioveta, Inc., Intervac Pvt. Ltd., Zoetis, Elanco, Merial, Merck & Co. Inc, Bayer Pharma AG, Ceva and Boehringer Ingelheim.

Want more insights?

Future Market Insights brings a comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The Middle East veterinary vaccines market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

The study provides compelling insights into the Middle East veterinary vaccines market. The veterinary vaccines market is segmented into five parts based on vaccine type (attenuated live vaccines, inactivated vaccines, toxoid vaccines, DNA vaccines, recombinant vaccines, and others) based on animal type (companion animals, livestock animals, and equine) based on disease indication (foot and mouth disease, Newcastle disease, PPRS, canine parvovirus, brucellosis, avian influenza, and others), based on end-user (hospital pharmacies, veterinary clinics, private veterinary pharmacies and others) and based on country ( KSA, UAE, Turkey, Jordan, Sudan, Egypt and Rest of MEA).

Purchase a Complete Research Report
https://www.futuremarketinsights.com/checkout/3086

Middle East Veterinary Vaccines, by Category

By Vaccine:

Attenuated Live Vaccines
Inactivated Vaccines
Toxoid Vaccines
DNA Vaccines
Recombinant Vaccines
Others

By Animal:

Companion Animals
Canine
Avian
Feline
Livestock Animals
Aquatic
Bovine
Porcine
Small Ruminant
Poultry
Equine

By Disease Indication:

Foot and Mouth Disease
Newcastle Disease
PPRS
Canine Parvovirus
Brucellosis
Avian Influenza
Others

Author

Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Global Point-of-Care Breathalyzer Market for Remarkable Growth, Expected to Reach USD 658.9 Million by 2032 at a 5.5%of CAGR

The global Point-of-Care Breathalyzer market is projected to experience significant growth, with an anticipated valuation of USD 385.7 million in 2022. According to market forecasts, the market is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.5%, reaching approximately USD 658.9 million by 2032. This growth is primarily attributed to the increasing consumption of alcohol worldwide.

From 2016 to 2021, the point-of-care breathalyzer market registered a CAGR of 5.2%, reflecting steady growth driven by the rising need for effective and reliable alcohol detection methods. As alcohol consumption continues to rise, the demand for point-of-care breathalyzers is expected to increase, supporting market expansion.

Your Insightful Report Sample With Your Work Email:
https://www.futuremarketinsights.com/reports/sample/rep-gb-2286

The word “Breathalyzer” has been used to refer to a variety of devices, including Alcotest, Alcosensor, Datamaster, Intoxilyzer, and Intoximeter, since 1954. The Breathalyzer device is made up of three parts: the breath sample system, the two chemical-containing glass tubes, and the photocells that are connected to the meter and show a color shift.

The Breathalyzer device employs a redox reaction to produce a color shift in dichromate ions that is exactly proportionate to the amount of alcohol in breath. The dichromate ion’s red-orange color changes to green.

Point-of-Care Breathalyzer Market: Drivers and Restraints

Point-of-care Breathalyzer market has seen enormous growth due to its significant use to maintain safety, order and discipline amongst population. The major drivers for point-of-care Breathalyzer market is alarming increase in alcohol consumption seen at all age groups and also increase in road accidents due to drink driving.

Due to strict government regulations, drink driving and alcohol abuse during work hours has led to increase in demand for modern use portable Breathalyzer. Use of personal portable Breathalyzer to check for alcohol content within normal limits to keep a check on safe driving and productive working hours has given a drive for point-of-care Breathalyzer market worldwide.

Moreover easy availability of personal Breathalyzer that can be ordered online according to ones choice, has also been a factor to drive point-of-care Breathalyzer market. Awareness initiative taken by government has also led to increase of market size for point-of-care Breathalyzer market.

High cost of Breathalyzer and less market for new brands producing Breathalyzer were seen to hamper in the past for but modern portable cheap Breathalyzer are taking over the point-of-care Breathalyzer market now.

Point-of-Care Breathalyzer Market: Overview

According to a study report published in South Africa about 10% of the country’s GDP is lost due to alcohol abuse annually which is equal to R240 billion. Also worldwide there is much loss due to alcohol abuse leading to immense destruction in drunk driving accidents, expensive alcohol abuse treatment and loss of manpower and productive working hours brings an overall effect on worldwide economy.

Thus awareness due to such losses have led government to take strict measures in field of law enforcement and highway safety administration to bring down losses. Efficient use of point-of-care Breathalyzer to prevent such loss has proved beneficial and made people aware of its legal consequences being the reason for increasing market for of point-of-care Breathalyzer market.

Mandatory alcohol test are carried out worldwide in workplaces such as transport, construction sites mining, shipping, airlines, defense centres, rehabilitation centres to maintain safety of individuals increasing market size for point-of-care Breathalyzer market over globe.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-2286

Point-of-Care Breathalyzer Market: Key Players

Some of the key players in point-of-care Breathalyzer market include Drägerwerk AG & Co. KGaA, Intoximeters,Lion Laboratories Limited, Lifeloc Technologies, Inc., Inc., , BACtrack, Quest Products, Inc., Alere, Inc., and C4 Development, Andatech Private Limited Ltd. Most of the providers of point-of-care breathalyzer are adopting the strategy of providing these products through e-commerce, so that buyers can browse the products according to their needs.

Based on product type, the point-of-care breathalyzer market is segmented into the following:

Desktop Point-of-Care Breathalyzer
Portable Point-of-Care Breathalyzer
Handheld Point-of-Care Breathalyzer

Based on product technology, the point-of-care breathalyzer market is segmented into the following:

Chemical reaction (Breathalyzer).
Fuel-cell technology (Alcosensor III or IV).
Infrared Spectroscopy (Intoxilyzer).

Based on end user, the point-of-care breathalyzer market is segmented into the following:

International and National transport systems.
Rehabilitation centres.
Government and private offices.
Diagnostic centers.
Home care settings

In-Depth Market Analysis: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/2286

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Branded Generics Industry Set for Explosive Growth at 8.6% CAGR, Reaching US$747.2 Million by 2033 | FMI Study

The Global Branded Generics Industry is on track for a significant expansion, driven by a rapidly evolving healthcare landscape and shifting market dynamics. A recent report by Future Market Insights (FMI), a leading market research firm, predicts substantial growth for this sector. The market is expected to surge from an estimated value of US$327.8 million in 2023 to a staggering US$747.2 million by 2033, reflecting a robust Compound Annual Growth Rate (CAGR) of 8.6%.

The surge in the branded generics market can be attributed to several key factors. Firstly, the expiration of patents for numerous blockbuster drugs has opened avenues for the introduction of branded generics, facilitating increased competition and affordability. Moreover, as chronic illnesses continue to afflict populations worldwide, there is a growing demand for accessible and cost-effective healthcare solutions. Branded generics, alongside pharmaceuticals reintroduced under new brand names, serve as vital components in addressing diverse medical conditions, bolstering the generic drug sector significantly.

Request a Sample of this Report Using a Work Email To Get a Quick Reply!
https://www.futuremarketinsights.com/reports/sample/rep-gb-1260

Since branded generics are free from patenting, companies are investing handsome amounts in this drug category. The market is set to reach a valuation of around 283.2 Bn in 2021, with top players in tier-1 accounting for 20%-25% market share.

The entry of new players, simple market authorization procedures, greater profit margin, and off-invoice discounts will expand the Global Branded Generics Industry during the forecast period.

As per the FMI’s analysis, despite the slight setback due to the pandemic, the Global Branded Generics Industry registered year-on-year (Y-o-Y) growth at 4.9% CAGR during 2020-2021.

“Rising demand for branded generics across both developing and developed economies along with high penetration of pharmaceutical industry will offer lucrative growth opportunities for the branded generics manufacturers during the forecast period,” says the FMI analyst.

Key Takeaways from FMI’s Global Branded Generics Industry Study

China and India are spearheading the growth of the Asia Pacific market spurred by the increasing adoption of branded generics by large-scale pharmacy chains in the emerging economies
The U.S. will lead North America’s branded generics market, registering a growth at 3.83% CAGR during the forecast period.
The market in India is expected to offer lucrative growth opportunities to branded generics manufacturers backed by the expansion of the pharmaceutical industry
In terms of therapeutic application, cardiovascular diseases and diabetes are expected to account for a considerable market share
Oral solid-dose pharmaceutical formulation continues to be highly preferred among patients. The oral segment accounts for over 55% share of the global branded generics market.

Global Branded Generics Industry Competitive Landscape

Teva, Abbott Laboratories, Novartis, Mylan, and Pfizer are some prominent players operating in the Global Branded Generics Industry cumulatively holding around 20-25% market share.

Key players operating in the branded generic market are focusing on expanding their business in emerging markets. They are adopting various organic and inorganic growth strategies such as mergers and acquisitions, advanced product development, and collaborations to gain a competitive edge in the market.

In October 2020, Glenmark Pharmaceuticals introduced NINDANIB (Nintedanib) for the treatment of pulmonary fibrosis in India. Glenmark has been amongst the first to launch the branded generic version at an affordable cost for the treatment of pulmonary fibrosis in India.

Click Here To Purchase Your Detailed Report
https://www.futuremarketinsights.com/checkout/1260

Global Branded Generics Industry by Category Therapeutic Application:

Oncology
Cardiovascular Diseases
Diabetes
Neurology
Gastrointestinal Diseases
Dermatology Diseases
Analgesics and Anti-inflammatory
Others

Drug Class:

Alkylating Agents
Antimetabolites
Hormones
Anti-Hypertensive
Lipid Lowering Drugs
Anti-Depressants
Anti-Psychotics
Anti-Epileptics
Others

Formulation Type:

Oral
Parenteral
Topical
Others

Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Global Diagnostic X-Ray System Market to Reach USD 20.46 Billion by 2032 at a 6.1%of CAGR

The global Diagnostic X-Ray System market is on a growth trajectory, with an estimated valuation of USD 11.30 billion by the end of 2022. According to a recent study by Future Market Insights, the market is expected to expand at a Compound Annual Growth Rate (CAGR) of 6.1%, reaching approximately USD 20.46 billion by 2032. Medical x-ray devices are leading the market, accounting for over 65% of the global share in 2021.

The increasing prevalence of chronic diseases, advancements in imaging technologies, and the growing emphasis on early diagnosis are driving the demand for diagnostic x-ray systems. These systems play a crucial role in medical diagnostics, providing vital information for the detection and management of various health conditions.

Your Insightful Report Sample With Your Work Email:
https://www.futuremarketinsights.com/reports/sample/rep-gb-667

In the ten years since the introduction of medical equipment with artificial intelligence and Internet of Things integration, the healthcare sector has grown significantly. Technology development has greatly expanded the possibilities for medical diagnosis and therapy.

The analysis provides substantial data sets that validate important trends propelling the market growth for diagnostic x-ray systems. It provides information on the tactics used by the top businesses to identify and resolve issues that are predicted to impede the market’s expansion for diagnostic x-ray systems. Our thorough examination and understanding of the historical, present, and projected market conditions enable the Diagnostic X-Ray System market study to assist in identifying the issues and providing solutions that will ensure the success of small and medium-sized businesses.

Key highlights of the comprehensive analysis on the Diagnostic X-Ray System market include:

Market Size and Growth Trends: Projections indicate robust growth in the Diagnostic X-Ray System market, with a CAGR of 6.1% and predicted values reaching US$ 20.46 billion by 2032.
Dominance of Medical X-Ray Devices: Medical x-ray devices are expected to maintain the largest market share in 2021, underscoring their significance in diagnostic imaging procedures.
Technological Advancements: Ongoing advancements in medical imaging technology, including digital radiography and computed tomography (CT), are driving innovation and enhancing the diagnostic capabilities of x-ray systems.
Global Market Dynamics: The analysis provides insights into market dynamics, including drivers, restraints, opportunities, and challenges shaping the growth trajectory of the Diagnostic X-Ray System market across different regions.

Competitive Landscape:

The market for diagnostic X-Ray systems is highly fragmented. Increased application in the field of healthcare, as well as security purposes, has led many companies to enter the market by way of providing services or acquiring smaller companies offering these services in order to maintain as well as grow their current market position.

In August 2022, Thermo Fisher Scientific Inc. partnered with Structura Biotechnology Inc., in order to develop a single particle analysis software solution, which will integrate Thermo Fisher’s Smart EPU software with a cryo-transmission electron microscope (cryo-TEM) technology.
In March 2022, Canon Medical Systems Corporation acquired Nordisk Rntgen Teknik A/S, a Danish firm to develop a cutting-edge technology to produce and manufacture screening X-ray systems

Similarly, recent developments related to companies manufacturing diagnostic x-ray systems have been tracked by the team at Future Market Insights, which are available in the full report.

Diagnostic X-Ray System Market: Segmentation

By Region

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa (MEA)

Detailed analysis on the geographical region and country wise insights are offered in the latest Diagnostic X-Ray System market report with established market players as well as incumbents in the region.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-667

Key Market Segments Covered in Diagnostic X-Ray System Industry Research

By Product:

Medical X-ray Devices
- Fixed/floor mounted
- Mobile and Portable Devices
X-Ray Diffraction (XRD)
- Powder Diffraction
- High-Resolution XRD
- Custom XRD
Security X-Ray Devices
- Closed X-Ray Systems
- Full body scanner
  - Single View
  - Dual View
X-Ray Fluorescence (XRF)
SAXS/WAXS

By Application:

Medical
Research and Development
Security

By End User:

Hospital
Diagnostic Imaging Centers
Airports
Malls
Railway & Metro Stations
Government Facilities & Homeland Security

Comprehensive analysis of the regional markets offers exclusive insights on the market performance across geographies along with relevant graphs, figures, and list of tables.

Competitive Analysis

By Prominent Market Players

Shimadzu Corporation
Medlink Imaging, LLC
Konica Minolta Healthcare Americas, Inc.
Leidos
ODSecurity
Rigaku Corporation
Anton Paar GmbH
Braun & Co. Limited
Xenoc
Proto Manufacturing
OSI Systems
Siemens Healthineers
General Electric Company
FUJIFILM Holdings Corp
Koninklijke Philips N.V.
Carestream Health
Canon Medical Systems Corporation
Smiths Detection Group Ltd
Thermo Fisher Scientific Inc.
Astrophysics Inc.
Malvern Panalytical Ltd
NUCTECH COMPANY LTD
Bruker

Get Full Market Analysis Now: Purchase The Report:
https://www.futuremarketinsights.com/checkout/667

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Urinary Tract Infection (UTI) Treatment Industry Set for Steady Growth at 1.9% CAGR, Reaching US$13.6 Billion by 2034 | FMI Study

The Global Urinary Tract Infection (UTI) Treatment Industry is poised for consistent growth over the next decade, driven by the high prevalence of UTIs and increasing healthcare awareness. According to a recent assessment, the market was valued at an estimated US$11.244 billion in 2024. Looking ahead, the market is projected to reach US$13.617.4 million by 2034, reflecting a Compound Annual Growth Rate (CAGR) of 1.9%.

The urinary tract infection treatment market is poised for substantial growth in the foreseeable future, attributed to factors such as hormonal changes, inadequate personal hygiene practices, catheter usage, and other contributing factors. As the prevalence of urinary tract infections rises, the market is anticipated to experience noteworthy expansion in the coming years.

The heightened occurrence of chronic kidney diseases, including conditions like bladder cancer and renal failure, has resulted in a greater utilization of catheters and other drainage devices among patients. Individuals using urinary catheters face an elevated risk of developing complicated urinary tract infections, driving the demand for UTI treatment.

Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-1340

Supportive government policies, initiatives, and regulations can influence the market positively by fostering research and development in the field of UTI treatment. Increased spending on healthcare infrastructure and services, both in developed and developing countries, can positively influence the UTI treatment market.

The adoption of telehealth and remote patient monitoring technologies can facilitate better management and follow-up care for individuals with UTIs. Growing awareness among patients and healthcare professionals about the importance of early detection and prompt treatment of UTIs can contribute to market growth.

Global Urinary Tract Infection (UTI) Treatment Industry Key Takeaways

From 2019 to 2023, the urinary tract infection (UTI) treatment market was valued at a CAGR of 2.1%
Based on indication, the uncomplicated UTI segment is expected to account for a share of 76.2% in 2024.
Global urinary tract infection (UTI) treatment demand in China is predicted to account for a CAGR of 2.0% in 2024.
In the United States, the urinary tract infection (UTI) treatment industry is expected to account for a CAGR of 2.5% in 2024.
India is projected to expand by a value CAGR of 1.9% between 2024 and 2034.
The urinary tract infection (UTI) treatment market in Japan is anticipated to record a CAGR of 2.1% in 2024.

“Increased prevalence of urinary tract infections and strategic advancements in treatment options propel the growth of the urinary tract infection treatment market.” says an FMI analyst.

Global Urinary Tract Infection (UTI) Treatment Industry Competitive Landscape

The market players are investing in ongoing research and development activities to discover and develop new and more effective UTI treatment options. This could involve the exploration of novel antibiotics, combination therapies, and innovative drug delivery methods. Expanding market presence by entering new geographic regions and enhancing distribution networks to ensure wider availability of UTI treatments.

Bristol-Myers Squibb Company focuses on the development of drugs in various therapeutic areas, including infectious diseases. They might have products related to UTI treatment.
Janssen Global Services LLC is a pharmaceutical company under the umbrella of Johnson & Johnson. They may have products related to infectious diseases, including UTI treatment.
Lupin is an Indian multinational pharmaceutical company. They might have a range of pharmaceutical products, including those related to infectious diseases.

More Valuable Insights Available

Future Market Insights offers an unbiased analysis of the global urinary tract infection (UTI) treatment market, providing historical data from 2019 to 2023 and forecast statistics between 2024 and 2034.

To understand opportunities in the urinary tract infection (UTI) treatment industry, the industry is segmented based on Drug Class (Penicillin & Combinations, Quinolones, Cephalosporin, Aminoglycoside Antibiotics, Sulphonamides (Sulfamethoxazole, Trimethoprim), Azoles and Amphotericin B, Tetracycline (Doxycycline), Nitrofurans (Nitrofurantoin), Others) By Indication(Complicated Urinary Tract Infection, Uncomplicated Urinary Tract Infection) By Distribution Channel(Hospital Pharmacies, Gynecology and Urology Clinics, Drug Stores, Retail Pharmacies, Online Drug Stores) Region (North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia, and the Middle East and Africa).

Key Players operating in the Global Urinary Tract Infection (UTI) Treatment Industry are

Allergan
Bayer AG
Pfizer, Inc.
GlaxoSmithKline plc
Bristol-Myers Squibb Company
Janssen Global Services, LLC
Lupin Ltd
Merck & Co., Inc.
Almirall, S.A
Dr. Reddy’s Laboratories Ltd.

Click Here To Purchase Your Full Report
https://www.futuremarketinsights.com/checkout/1340

Global Urinary Tract Infection (UTI) Treatment Industry – Key Segments

By Drug Class:

Penicillin & Combinations
Quinolones
Cephalosporin
Aminoglycoside Antibiotics
Sulphonamides (Sulfamethoxazole, Trimethoprim)
Azoles and Amphotericin B
Tetracycline (Doxycycline)
Nitrofurans (Nitrofurantoin)
Others

By Indication:

Complicated
Uncomplicated

By Distribution Channel:

Hospital Pharmacies
Gynecology and Urology Clinics
Drug Stores
Retail Pharmacies
Online Drug Stores

By Region:

North America
Latin America
Western Europe
Eastern Europe
South Asia and the Pacific
East Asia
Middle East and Africa

About the Healthcare Division at Future Market Insights

The healthcare team at Future Market Insights offers expert analysis, time-efficient research, and strategic recommendations to provide authentic insights and accurate results to help clients worldwide.

With a repertoire of over 100+ reports and 1 billion+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis of key trends including competitive landscape, profit margin, and research development efforts.

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Global Liver Transplant Market Set to Soar, Predicted to Reach USD 2,653.4 Million by 2033 at a 6.5% of CAGR

The global liver transplantation market is experiencing robust growth, driven by increasing demand for healthy liver solutions. The current market value is estimated at USD 1,409.8 million in 2023, with expectations to nearly double to around USD 2,653.4 million by 2033. The market is anticipated to grow at a steady Compound Annual Growth Rate (CAGR) of 6.5% during the forecast period.

The rising incidence of liver diseases, advancements in transplantation technology, and increasing awareness about liver health are key factors fueling market growth. As more patients seek effective treatment options for liver conditions, the demand for liver transplants continues to rise, driving the market forward.

Your Insightful Report Sample With Your Work Email:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1281

The market for liver transplants is expected to develop in the near future, with improvements in treatment techniques expected to contribute significantly to this growth. The government’s and some private healthcare facilities’ reimbursement policies have led to an increase in the market for liver transplants.

Weforum (2022) reports that over 130,000 organ transplants were completed in 2020. The liver and heart were the next most common organs, after the kidney. A small number of companies that manufacture surgical instruments and preservation techniques control the majority of the liver transplant market.

For example, a group of Swiss doctors came up with a novel way in June 2022 to shorten the waiting list for organ transplants. In addition, the surgeons created a novel technique to sustain a damaged liver for a few days. In order to see encouraging progress, the staff is still keeping an eye on the patient.

The transplant waiting list may be shortened by developing new methods for storing injured livers as well as conducting efficient stem cell, tissue engineering, and organogenesis research and development.

Key Takeaways :

The North American region showed a 29.2% share of the liver transplantation market.
European nations also show promising market demand in the liver transplantation market, with a share of 20.7%.
Based on treatment type, liver transplantation surgery dominates the liver transplantation market with a 61.1% global revenue share.
According to the forecast, 51% of liver transplantation surgeries are done in hospitals, while the rest are done in ambulatory and adult liver transplantation centers.

Recent Developments Detected by FMI in the Liver Transplantation Market:

In 2022, Jaslok Hospital and Research Center in Mumbai saved two lives with a single liver transplantation surgery. This transplantation surgery, also known as split cadaver liver donation surgery, is where the liver is split into two. It was then used by both an adult and a pediatric recipient simultaneously.

In August 2022, Integrated Graphene, with a team of scientists, developed an electrochemical biosensor to detect biliary complications in donor livers. The device, Gii-Sens, can detect the quality of the liver before transplantation. It can prevent the development of biliary complications and match the donor-recipient for transplant. According to the makers of Gii-Sens, the device is portable, economical, and responds fast to point-of-care diagnostics.

Key Players:

Allosource
Conatus Pharmaceuticals Inc.
Digna Biotech S.L.
Dompe Farmaceutici S.p.A.
Isogenis, Inc.
RedHill Biopharma Ltd.
Thompson Surgical
Integra Life Sciences
Baxter International Inc.
XVIVO
VirTech Bio
Vital Therapies
HepaTx
Humedics

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-1281

Key Segments Profiled in the Global Liver Transplantation Market:

By Treatment Type:

Liver Transplantation Surgery
Post-Surgery Anti-Rejection Treatment
Cyclosporine
Tacrolimus
Sirolimus Prednisone Azathioprine
Mycophenolate Mofetil

By End Use:

Hospitals
Adult Liver Transplantation Centers
Ambulatory Surgical Centers

By Region:

North America
Latin America
Europe
Asia Pacific
The Middle East and Africa

Get Full Market Analysis Now: Purchase The Report:
https://www.futuremarketinsights.com/checkout/1281

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Empty Capsules Industry Poised for Explosive Growth, Reaching US$6.4 Billion by 2034, at an 8% of CAGR | FMI Analysis

The Global Empty Capsules Industry is on the cusp of a significant expansion, fueled by a growing demand for convenient and effective drug delivery solutions. According to market research, the industry is projected to reach a staggering US$6,378.6 million by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 8% from 2024 onwards. This press release highlights the key drivers propelling this remarkable market growth.

The surge in demand for empty capsules can be attributed to the escalating frequency of chronic diseases and the increasing popularity of dietary supplements. Recognized as a swift and convenient method for drug consumption, empty capsules offer a hassle-free alternative, less prone to induce adverse effects compared to other dose forms.

Driving Factors Behind Surging Demand for Global Empty Capsule Industry

The primary drivers behind the surging demand for empty capsules are twofold. First, there is a noticeable uptick in the popularity of capsules as the preferred form of drug delivery. This shift is further accentuated by the increasing consumption of various medications. Secondly, as the global burden of chronic diseases continues to escalate, the demand for effective therapeutics is expected to surge, presenting lucrative opportunities for suppliers of empty capsules.

Request a Sample Copy of This Report Using a Work Email To Get a Quick Reply.
https://www.futuremarketinsights.com/reports/sample/rep-gb-782

A Promising Future for the Global Empty Capsules Industry

In summary, the future of the Global Empty Capsules Industry appears incredibly promising, with robust growth prospects anticipated in the years ahead. Key industry players operating in the market are well-positioned to benefit from this trend, provided they adapt to evolving consumer preferences and invest in product innovation to maintain a competitive edge.

Empty capsules are known as protective shells for drugs designed from special film-forming materials such as gelatin, starch, and pullulan. Being innovative drug delivery products, they are utilized by leading pharmaceutical and biopharmaceutical companies due to their various attractive features. Such capsules are economical, oxidation resistant, offer maximum flexibility, and are easy to use on account of their smooth and slippery nature. Furthermore, they are especially suitable for substances having a bitter taste and unpleasant odor.

Global Empty Capsule Industry Key Takeaways

Unprecedented Growth: The global empty capsule market is projected to reach a significant value of US$ 2,956.6 million in 2024, with a compelling 8% Compound Annual Growth Rate (CAGR) expected from 2024 to 2034, ultimately reaching US$ 6,378.6 million by 2034.
Rising Demand Due to Chronic Diseases: The increasing prevalence of chronic diseases worldwide is a major driving force behind the surge in demand for empty capsules. These capsules offer an efficient and convenient method for drug consumption, catering to the needs of patients and healthcare providers alike.
Popularity of Dietary Supplements: The industry is experiencing a spike in demand, driven by the growing popularity of dietary supplements. Empty capsules are recognized as a preferred choice for the delivery of supplements, contributing to the overall growth of the market.
Ease of Use and Reduced Side Effects: Empty capsules provide a quick and easy means of drug consumption and are less likely to induce negative effects compared to other dose forms. This inherent advantage is further propelling the increased adoption of empty capsules in the pharmaceutical and healthcare sectors.
Paradigm Shift in Drug Formulation: As the market expands, there is a noticeable shift in the pharmaceutical and nutraceutical sectors towards embracing the benefits of empty capsules for drug formulation. This shift indicates a changing landscape in the way drugs are developed and delivered.
Strategic Implications for Stakeholders: Stakeholders in the pharmaceutical and healthcare sectors are advised to recognize and adapt to the dynamic landscape of the empty capsule market. With a projected market value of US$ 6,378.6 million by 2034, staying informed about industry trends and innovations is crucial for staying competitive.
Transformative Journey Ahead: The global empty capsule market is on the verge of a transformative journey, and industry players should proactively position themselves to capitalize on the opportunities presented by this substantial growth in the coming decade.

Global Empty Capsule Industry Competitive Landscape

The Global Empty Capsules Industry is known to be highly competitive in nature attributed to the presence of leading empty pill manufacturers that account for over 70% of the global market share. Prominent market players are constantly focusing on introducing new products designed out of innovative materials. In addition to that, they are adopting growth strategies such as partnerships, mergers, acquisitions, etc. to expand their global footprint.

List encompassing key players operating in the Global Empty Capsules Industry

ACG Worldwide
Capsugel
Qualicaps Inc.
Bright Pharma Caps Inc.
Sunil Healthcare Ltd.
CapsCanada Corporation
Roxlor LLC
Snail Pharma Industry Co. Ltd.
Suheung Co. Ltd.
Medi-Caps Ltd

Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/782

Key Segments of Global Empty Capsules Industry Survey

Capsule Size:

Size “000” Empty Capsules
Size “00” Empty Capsules
Size “0” Empty Capsules
Size “1” Empty Capsules
Size “2” Empty Capsules
Size “3” Empty Capsules
Size “4” Empty Capsules
Size “5” Empty Capsules

Product Type:

Gelatin (Hard)-based Capsules
Vegetarian-based Capsules

Route of Administration:

Empty Capsules for Oral Administration
Empty Capsules for Inhalation

Raw Material:

Contract Type-A (Pork Skin) Empty Capsules
Type-B Gelatin (Animal Bones & Calf Skin) Empty Capsules
Fish Bone Gelatin Empty Capsules
Empty Hydroxy Propyl Methyl Cellulose (HPMC) Empty Capsules
Starch Material Empty Capsules
Empty Pullulan Capsules

End User:

Empty Capsules for Pharmaceutical Companies
Empty Capsules for Cosmetic & Nutraceutical Companies
Empty Capsules for Clinical Research Organizations (CROS)

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Global Electronic Medical Records Industry Booming: Projected to Reach US$34.34 Billion by 2034 at a 6.2% CAGR | FMI Study

The Global Electronic Medical Records Industry is poised for significant expansion, driven by the increasing adoption of digital healthcare solutions. According to a recent analysis, the market is projected to reach a valuation of US$34.34 billion by 2034. This translates to a healthy Compound Annual Growth Rate (CAGR) of 6.2% over the next decade. The current market size is estimated to be US$18.82 billion in 2024, reflecting a steady rise in the implementation of EMR systems across healthcare facilities.

As healthcare organizations worldwide recognize the imperative benefits of electronic medical records, the market is expected to witness substantial expansion. The heightened demand is directly correlated to the industry’s recognition of electronic health records as software-as-a-service, facilitating scalability and streamlined operations for multiple healthcare providers.

Request a Sample of this Report Using a Work Email To Get a Quick Reply!
https://www.futuremarketinsights.com/reports/sample/rep-gb-387

The market is expanding as a result of an increase in the number of benefits, including lower infrastructure and maintenance expenses, lower license and start-up costs, and greater accessibility. Improved productivity and quicker, simpler adoption are two benefits of cloud-based EMR solutions. The application is incredibly scalable because of its cloud-based architecture (pay-as-you-go storage utilization). It removes departmental silos of healthcare data to streamline and consolidate storage resources to reduce costs and boost efficiency.

Large, well-known firms are starting to enter the cloud sector. To maintain the level of patient care, the cloud infrastructure also provides real solutions for business continuity and disaster recovery. As a result, the cloud-based EMR market is anticipated to expand dramatically. The digital revolution in healthcare is essential to give medical staff relatively easy access to patient records. During the projection period, it is predicted that the growing need for systems and software that connect hospitals, clinics, and other healthcare facilities will become a growth driver.

A greater emphasis is placed on strategic partnerships between leading suppliers of electronic medical record solutions as market rivalry intensifies. Additionally, it is projected that the constantly growing need for knowledge sharing and technology upgrades to improve healthcare efficiency will foster partnerships between important actors.

Key Takeaways from the Global Electronic Medical Records Industry

The US electronic medical records (EMR) market is anticipated to expand at a CAGR of 4.5% over the forecasted period.
The market for electronic medical records (EMR) in India is anticipated to expand at 6.8% over the forecasted period.
By 2033, the market for electronic medical records (EMR) is anticipated to reach more than US$ 34.34 billion
In 2021, the market for electronic medical records (EMR) was dominated by cloud-based EMRs, which accounted for more than 50.0% of total revenue.
Hospital electronic medical records (EMR) are expected to increase at a CAGR of 6.4% throughout the forecast period as a result of rising pandemic and epidemic infections, as well as the requirement for global vaccination against a wide range of diseases.

Who is Winning?

According to Future Market Insights (FMI), top EMR solution providers are building alliances with the local healthcare system, engaging in mergers and acquisitions, and bolstering their distribution networks to develop and explore the underdeveloped markets of Asia and Latin America. To break into middle-income and emerging markets, market companies are also concentrating on raising awareness, lowering the price of EMR software and related services, and fusing EMR with contemporary technologies.

Microsoft Corp. acquired Nuance Communications, Inc. in April 2021 to empower healthcare providers with the power of ambient clinical intelligence and other Microsoft cloud services.
Capital Health, a regional leader in providing cutting-edge, high-quality patient care, introduced a new electronic health record (EGR) in the acute care divisions of both of its hospitals in February 2021 to better serve its patients.
The “Patient” database personal health record (PHR) of the patient will now be able to safely transfer the patient’s existing health records from the “Patient” database onto the Apple Health app, according to a May 2021 announcement from DrChrono. This should simplify the procedure and make it easier to access medical data more quickly.

Grab Your Report on Discount Before It’s Gone!
https://www.futuremarketinsights.com/request-discount/rep-gb-387

Key Segments Covered in Global Electronic Medical Records Industry Study

By Product Type:

Hospital EMR
Ambulatory EMR

By Component:

EMR Software
EMR Services

By Application:

Client Server Setup EMR
Hybrid Server Setup EMR
Cloud Based EMR

By End User:

Hospitals
Specialized Clinics
General Physician Clinics
Ambulatory Surgical Centers

Author

Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us: